5 citations,
August 2018 in “Neurology and Therapy” Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
1 citations,
March 2019 in “Journal of Interdisciplinary Medicine” A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
45 citations,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
36 citations,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
12 citations,
July 1957 in “Journal of Investigative Dermatology” Giving dihydrotachysterol to mother rats caused skin hardening and bone issues in their babies through milk.
4 citations,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
March 2015 in “Polish Journal of Public Health” Blood vessel patterns in skin diseases relate to certain blood markers in systemic sclerosis but not in psoriasis or psoriatic arthritis, and may indicate circulation issues in alopecia.
29 citations,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
16 citations,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
11 citations,
April 2018 in “The Journal of urology/The journal of urology” Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.
2 citations,
July 2022 in “Dermatology Reports” EPDS and MS might share an immune-related cause.
2 citations,
June 1987 in “British Journal of Dermatology” Warming hands improves blood flow in people with systemic sclerosis.
1 citations,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
January 2022 in “Medical research archives” Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
1 citations,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
72 citations,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
1 citations,
January 2019 in “Przegla̧d dermatologiczny” Skin problems like psoriasis and systemic sclerosis can increase the risk of heart disease, so doctors should watch for heart risks in patients with these conditions.
June 2020 in “Annals of the Rheumatic Diseases” Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.
January 2012 in “Journal of Investigative Dermatology” Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.
August 1988 in “Journal of the Royal Society of Medicine” Hyperbaric oxygen therapy shows promise for multiple sclerosis, but skepticism and funding issues limit tech use in clinics, and outdated single-drug cancer treatments may cause unnecessary side effects.
August 2019 in “Reactions Weekly” Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
August 2022 in “Contact dermatitis” Severe allergic reactions to hair dye can trigger hair loss and may be linked to multiple sclerosis.
January 2016 in “Experimental Dermatology” New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.
January 2016 in “Journal of Investigative Dermatology” Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.
80 citations,
March 2004 in “Neuropediatrics” Coats' Plus is a genetic disorder with eye abnormalities, brain calcification, poor growth, bone and skin issues, and movement disorders.
40 citations,
September 2012 in “European Journal of Dermatology” Laser hair removal significantly improves acne keloidalis nuchae, especially with early treatment.
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Hair loss can indicate various health issues, including serious diseases, hormonal imbalances, and can significantly affect personal life and mental health.
March 2019 in “Journal der Deutschen Dermatologischen Gesellschaft” Rothmund-Thomson syndrome type 2 can cause chronic, poorly healing wounds.
April 2016 in “Journal of Clinical Research in Dermatology” A woman had skin and hair issues after a botulinum toxin injection.